Thromboangiitis obliterans (Buerger's disease): Searching for a therapeutic strategy

Angiology

Volumn 58, Issue 1, 2007, Pages 75-84

  Paraskevas, Kosmas I ^a,c   Liapis, Christos D ^a   Briana, Despina D ^b   Mikhailidis, Dimitri P ^c  

^a Department of Vascular Surgery ^*  (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BERAPROST; CYCLOPHOSPHAMIDE; GUANETHIDINE; HEPARIN; ILOPROST; LIDOCAINE; NICOTINE GUM; PLACEBO; PROSTAGLANDIN E1; SAPROGELATE; SEROTONIN ANTAGONIST; STREPTOKINASE; UNCLASSIFIED DRUG; UROKINASE; VASCULOTROPIN 165;

ADRENALECTOMY; AMPUTATION; ANALGESIA; ANGIOGENESIS; ARTERY RECONSTRUCTION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BUERGER DISEASE; CHEMICAL SYMPATHECTOMY; CIGARETTE SMOKING; CLINICAL TRIAL; CONTINUOUS INFUSION; DISEASE COURSE; DOSAGE SCHEDULE COMPARISON; DRUG DOSE COMPARISON; DRUG INFUSION; FOOT ULCER; HEPARINIZATION; HUMAN; INTERMITTENT CLAUDICATION; KIRSCHNER WIRE; LIMB ISCHEMIA; LOW DRUG DOSE; LUMBAR SYMPATHECTOMY; PERIPHERAL BLOOD MONONUCLEAR CELL; RAYNAUD PHENOMENON; REVIEW; SMOKING CESSATION; SPINAL CORD STIMULATION; SURGICAL TECHNIQUE; SYMPATHECTOMY; SYMPATHETIC BLOCKING; THORACIC SYMPATHECTOMY; TISSUE TRANSPLANTATION; TREATMENT OUTCOME; ULCER; ULCER HEALING; UNSPECIFIED SIDE EFFECT; VASCULAR SURGERY;

HUMANS; PHARMACEUTICAL PREPARATIONS; SMOKING CESSATION; SURGICAL PROCEDURES, OPERATIVE; THROMBOANGIITIS OBLITERANS;

EID: 33847015967     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003319706291169     Document Type: Review

References (99)

1. Buerger L: Thrombo-angiitis obliterans: a study of the vascular lesions leading to presenile spontaneous gangrene. Am J Med Sci 136: 567-580, 1908.
2. Olin JW: Thromboangiitis obliterans (Buerger's disease). N Engl J Med 343: 864-869, 2000.
3. No YJ, Lee EM, Lee DH, et al: Cerebral angiographic findings in thromboangiitis obliterans. Neuroradiology 47: 912-915, 2005.
4. Hoppe B, Lu JT, Thistlewaite P, et al: Beyond peripheral arteries in Buerger's disease: angiographic considerations in thromboangiitis obliterans. Catheter Cardiovasc Interv 57: 363-366, 2002.
5. Calguneri M, Ozturk MA, Ay H, et al: Buerger's disease with multisystem involvement. A case report and a review of the literature. Angiology 55: 325-328, 2004.
6. Inzelberg R, Bornstein NM, Korczyn AD: Cerebrovascular symptoms in thromboangiitis obliterans. Act Neurol Scand 80: 347-350, 1989.
7. Rai M, Miyashita K, Oe H, et al: Multiple brain infarctions in a young patient with Buerger's disease. A case report of cerebral thromboangiitis obliterans. Rinsho Shinkeigaku 44: 522-526, 2004.
8. Matchev S, Petrov V, Batchvarova V, et al: Transcranial Doppler velocities in patients with thromboangiitis obliterans. Angiology 48: 535-544, 1997.
9. Mills JL, Porter JM: Buerger's disease (thromboangiitis obliterans). Ann Vasc Surg 5: 570-572, 1991.
10. Nielubowicz J, Rosnowski A, Pruszynski B, et al: Natural history of Buerger's disease. J Cardiovasc Surg (Torino) 21: 529-540, 1980.
11. Mills JL Sr: Buerger's disease in the 21st century: diagnosis, clinical features, and therapy. Semin Vasc Surg 16: 179-189, 2003.
12. Olin JW, Shih A: Thromboangiitis obliterans (Buerger's disease). Curr Opin Rheumatol 18: 18-24, 2006.
13. Czarnacki M, Zdrojowy K, Adamiec R: Review of current etiopathogenic data of Buerger disease. Pol Merkuriusz Lek 13: 263-265, 2002.
14. Kurata A, Franke FE, Machinami R, et al: Thromboangiitis obliterans: classic and new morphological features. Virchows Arch 436: 59-67, 2000.
15. Corelli F: Buerger's disease: cigarette smoker disease may always be cured by medical therapy alone. Uselessness of operative treatment. J Cardiovasc Surg (Torino) 14: 28-36, 1973.
16. Hooten WM, Bruns HK, Hays JT: Inpatient treatment of severe nicotine dependence in a patient with thromboangiitis obliterans (Buerger's disease). Mayo Clin Proc 73: 529-532, 1998.
17. Lie JT: Thromboangiitis obliterans (Buerger's disease) and smokeless tobacco. Arthritis Rheum 31: 812-813, 1988.
18. Joyce JW: Buerger's disease (thromboangiitis obliterans). Rheum Dis Clin North Am 16: 463-470, 1990.
19. Makita S, Nakamura M, Murakami H, et al: Impaired endothelium-dependent vasorelaxation in peripheral vasculature of patients with thromboangiitis obliterans (Buerger's disease). Circulation 94: II-211 - II-215, 1996.
20. Yamamoto K, Iwase S, Mano T, et al: Muscle sympathetic outflow in Buerger's disease. J Auton Nerv Syst 44: 67-75, 1993.
21. Iwase S, Okamoto T, Mano T, et al: Skin sympathetic outflow in Buerger's disease. Auton Neurosci 87: 286-292, 2001.
22. Narkiewicz K, van de Borne PJ, Hausberg M, et al: Cigarette smoking increases sympathetic outflow in humans. Circulation 98: 528-534, 1998.
23. Celermajer DS, Adams MR, Clarkson P, et al: Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N Engl J Med 334: 150-154, 1996.
24. Chalon S, Moreno H Jr, Benowitz NL, et al: Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin Pharmacol Ther 67: 391-397, 2000.
25. Avcu F, Akar E, Demirkilic U, et al: The role of prothrombotic mutations in patients with Buerger's disease. Thromb Res 100: 143-147, 2000.
26. Brodmann M, Renner W, Stark G, et al: Prothrombotic risk factors in patients with thromboangiitis obliterans. Thromb Res 99: 483-486, 2000.
27. Kobayashi M, Ito M, Nakagawa A, et al: Immunohistochemical analysis of arterial wall cellular infiltration in Buerger's disease (endarteritis obliterans). J Vasc Surg 29: 451-458, 1999.
28. Matsushita M, Kuzuya A, Kobayashi M, et al: Buerger's disease in a 19-year-old woman. J Vasc Surg 38: 175-179, 2003.
29. Olin JW, Young JR, Graor RA, et al: The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease). Circulation 82: IV3 - IV8, 1990.
30. Lau H, Cheng SW: Buerger's disease in Hong Kong: a review of 89 cases. Aust N Z J Surg 67: 264-269, 1997.
31. Nakajima N: The change in concept and surgical treatment on Buerger's disease - personal experience and review. Int J Cardiol 66: S273 - S280, 1998.
32. Bozkurt AK, Besirli K, Koksal C, et al: Surgical treatment of Buerger's disease. Vascular 12: 192-197, 2004.
33. Shigematsu H, Shigematsu K: Factors affecting the long-term outcome of Buerger's disease (thromboangiitis obliterans). Int Angiol 18: 58-64, 1999.
34. Roncon-Albuquerque R, Serrao P, Vale-Pereira R, et al: Plasma catecholamines in Buerger's disease: Effects of cigarette smoking and surgical sympathectomy. Eur J Vasc Endovasc Surg 24: 338-343, 2002.
35. Brodde OE: Physiology and pharmacology of cardiovascular catecholamine receptors: implications for treatment of chronic heart failure. Am Heart J 120: 1565-1572, 1990.
36. Naik RS, Tripathi BP, Vaidya RC, et al: Buerger's disease versus adrenalectomy and sympathectomy. J Indian Med Assoc 71: 199-202, 1978.
37. Sayin A, Bozkurt AK, Tuzun H, et al: Surgical treatment of Buerger's disease: experience with 216 patients. Cardiovasc Surg 1: 377-380, 1993.
38. Sasajima T, Kubo Y, Inaba M, et al: Role of infrainguinal bypass in Buerger's disease: an eighteen-year experience. Eur J Vasc Endovasc Surg 13: 186-192, 1997.
39. Shindo S, Matsumoto H, Ogata K, et al: Arterial reconstruction in Buerger's disease: by-pass to disease-free collaterals. Int Angiol 21: 228-232, 2002.
40. Ohta T, Ishioashi H, Hosaka M, et al: Clinical and social consequences of Buerger disease. J Vasc Surg 39: 176-180, 2004.
41. Singh I, Ramteke VK: The role of omental transfer in Buerger's disease: New Delhi's experience. Aust N Z J Surg 66: 372-376, 1996.
42. Talwar S, Jain S, Porwal R, et al: Pedicled omental transfer for limb salvage in Buerger's disease. Int J Cardiol 72: 127-132, 2000.
43. Bhargava JS, Makker A, Bhargava K, et al: Pedicled omental transfer for ischaemic limbs-a 5-year experience. J Indian Med Assoc 95: 100-102, 1997.
44. Olshwang D, Beer G, Magora F: Intravenous regional guanethidine treatment in peripheral vascular disease. Angiology 31: 639-645, 1980.
45. Stumpflen A, Ahmadi A, Attender M, et al: Effects of transvenous regional guanethidine block in the treatment of critical finger ischemia. Angiology 51: 115-122, 2000.
46. Saha K, Chabra N, Gulati SM: Treatment of patients with thromboangiitis obliterans with cyclophosphamide. Angiology 52: 399-407, 2001.
47. Fiessinger JN, Schafer M: Trial of iloprost versus aspirin treatment for critical limb ischemia of thromboangiitis obliterans: The TAO Study. Lancet 335: 555-557, 1990.
48. The European TAO Study Group: Oral iloprost in the treatment of thromboangiitis obliterans (Buerger's disease): a double-blind, randomised, placebo-controlled trial. Eur J Vasc Endovasc Surg 15: 300-307, 1998.
49. Paraskevas KI, Trigka AA, Samara M: Successful intravenous regional sympathetic blockade (Bier's Block) with guanethidine and lidocaine in a patient with advanced Buerger's Disease (thromboangiitis obliterans)-a case report. Angiology 56: 493-496, 2005.
50. Hussein EA, el Dorri A: Intra-arterial streptokinase as adjuvant therapy for complicated Buerger's disease: early trials. Int Surg 78: 54-58, 1993.
51. Kawabata H, Kamakura T, Guti A, et al: Successful treatment of digital ulceration in Buerger's disease with nicotine chewing gum. Br J Derm 140: 187-188, 1999.
52. Rydzewski A, Urano T, Hachiya T, et al: The effect of 5HT2 receptor antagonist sarpogrelate (MCI-9042) treatment on platelet function in Buerger's disease. Thromb Res 84: 445-452, 1996.
53. Swigris JJ, Olin JW, Mekhail NA: Implantable spinal cord stimulator to treat the ischemic manifestations of thromboangiitis obliterans (Buerger's disease). J Vasc Surg 29: 928-935, 1999.
54. Chierichetti F, Mambrini S, Bagliani A, et al: Treatment of Buerger's disease with electrical spinal cord stimulation - review of three cases. Angiology 53: 341-347, 2002.
55. Manfredini R, Boari B, Gallerani M, et al: Thromboangiitis obliterans (Buerger disease) in a female mild smoker treated with spinal cord stimulation. Am J Med Sci 327: 365-368, 2004.
56. Pace AV, Saratzis N, Karokis D, et al: Spinal cord stimulation in Buerger's disease. Ann Rheum Dis 61: 1114-1114, 2002.
57. Donas KP, Schulte S, Ktenidis K, et al: The role of epidural spinal cord stimulation in the treatment of Buerger's disease. J Vasc Surg 41: 830-836, 2005.
58. Isner JM, Baumgartner I, Rauh G, et al: Treatment of thromboangiitis obliterans (Buerger's disease) by intramuscular gene transfer of vascular endothelial growth factor: preliminary clinical results. J Vasc Surg 28: 964-973, 1998.
59. Ishida A, Ohya Y, Sakuda H, et al: Autologous peripheral blood mononuclear cell implantation for patients with peripheral arterial disease improves limb ischemia. Circ J 69: 1260-1265, 2005.
60. Inan M, Alat I, Kutlu R, et al: Successful treatment of Buerger's disease with intramedullary K-wire: the results of the first 11 extremities. Eur J Vasc Endovasc Surg 29: 277-280, 2005.
61. Seibold JR, Allegar NE: The treatment of Raynaud's phenomenon. Clin Dermatol 12: 317-321, 1994.
62. Sulzberger MB: Hypersensitivity to tobacco glyco-protein in human peripheral vascular disease. Ann Allergy 47: 476-476, 1981.
63. Gulati SM, Madhra K, Thusoo TK, et al: Autoantibodies in thromboangiitis obliterans (Buerger's disease). Angiology 33: 642-651, 1982.
64. Gulati SM, Saha K, Kant L, et al: Significance of circulatory immune complexes in thromboangiitis obliterans (Buerger's disease) Angiology 35: 276-281, 1984.
65. Adar R, Papa MZ, Halpern Z, et al: Cellular sensitivity to collagen in thromboangiitis obliterans. N Engl J Med 308: 1113-1116, 1983.
66. Slavov ES, Stanilova SA, Petkov DP, et al: Cytokine production in thromboangiitis obliterans patients: new evidence for an immune-mediated inflammatory disorder. Clin Exp Rheumatol 23: 219-226, 2005.
67. Kroger K, Kreuzfelder E, Moser C, et al: Thromboangiitis obliterans: leucocyte subpopulations and circulating immune complexes. Vasa 30: 189-194, 2001.
68. Maslowski L, McBane R, Alexewicz P, et al: Antiphospholipid antibodies in thromboangiitis obliterans. Vasc Med 7: 259-264, 2002.
69. de Godoy JM, Braile DM, Godoy MF: Buerger's disease and anticardiolipin antibodies: a worse prognosis ? Clin Appl Thromb Hemost 8: 85-86, 2002.
70. Lee T, Seo JW, Sumpio BE, et al: Immunobiologic analysis of arterial tissue in Buerger's disease. Eur J Vasc Endovasc Surg 25: 451-457, 2003.
71. Mach F: Statins as immunomodulatory agents. Circulation 109: II15 - II17, 2004.
72. Steffens S, Mach F: Anti-inflammatory properties of statins. Semin Vasc Med 4: 417-422, 2004.
73. Benthin NP: Ilomedin (iloprost) and Buerger disease. Ugeskr Laeger 157: 4946-4947, 1995.
74. Bozkurt AK, Koksal C, Ercan M: The altered hemorheologic parameters in thromboangiitis obliterans: a new insight. Clin Appl Thromb Hemost 10: 45-50, 2004.
75. Zheng P, Chen SJ, Shao HZ: Studies on hypercoagulation state in thromboangiitis obliterans. Chin Med J (Engl) 102: 67-71, 1989.
76. Szendro G, Golcman L, Cristal N: Study of the factors affecting blood viscosity in patients with thromboangiitis obliterans. A preliminary report. J Vasc Surg 7: 759-762, 1988.
77. Poliantsev AA, Mozgovoi PV, Frolov DV, et al: Effect of Buerger's thromboangiitis activity on the outcomes of vascular reconstruction. Angiol Sosud Khir 10: 91-96, 2004.
78. Carr ME Jr, Hackney MH, Hines SJ, et al: Enhanced platelet force development despite drug-induced inhibition of platelet aggregation in patients with thromboangiitis obliterans-two case reports. Vasc Endovascular Surg 36: 473-480, 2002.
79. Pietraszek MH, Choudhury NA, Baba S, et al: Serotonin as a factor involved in pathophysiology of thromboangiitis obliterans. Int Angiol 12: 9-12, 1993.
80. Choudhury NA, Pietraszek MH, Hachiya T, et al: Plasminogen activators and plasminogen activator inhibitor 1 before and after venous occlusion of the upper limb in thromboangiitis obliterans (Buerger's disease). Thromb Res 66: 321-329, 1992.
81. Musial J, Wilczynska M, Sladek K, et al: Fibrinolytic activity of prostacyclin and iloprost in patients with peripheral arterial disease. Prostaglandins 31: 61-70, 1986.
82. Milionis HJ, Elisaf MS, Mikhailidis DP: The effects of lipid-regulating therapy on haemostatic parameters. Curr Pharm Des 9: 2425-2443, 2003.
83. Brumeanu TD, Goldstein R, Casares S: Down-regulation of autoreactive T-cells by HMG CoA reductase inhibitors. Clin Immunol 119: 1-12, 2006.
84. Riboldi P, Gerosa M, Meroni PL: Statins and autoimmune diseases. Lupus 14: 765-768, 2005.
85. Nagashima H, Kasanuki H: Therapeutic value of statins for vascular remodeling. Curr Vasc Pharmacol 1: 273-279, 2003.
86. Calabro P, Yeh ET: The pleiotropic effects of statins. Curr Opin Cardiol 20: 541-546, 2005.
87. Liao JK: Clinical implications for statin pleiotropy. Curr Opin Lipidol 16: 624-629, 2005.
88. Ghajar AW, Miles JB: The differential effect of the level of spinal cord stimulation on patients with advanced peripheral vascular disease in the lower limbs. Br J Neurosurg 12: 402-408, 1998.
89. Claeys LG, Horsch S: Transcutaneous oxygen pressure as predictive parameter for ulcer healing in end-stage vascular patients treated with spinal cord stimulation. Int Angiol 15: 344-349, 1996.
90. Banai S, Jaklitsch MT, Shou M, et al: Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 89: 2183-2189, 1994.
91. Takeshita S, Zheng LP, Brogi E, et al: Therapeutic angiogenesis. A single intraarterial bolus of vascular endothelial growth factor augments revascularization in a rabbit ischemic hind limb model. J Clin Invest 93: 662-670, 1994.
92. Hariawala MD, Horowitz JR, Esakof D, et al: VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 63: 77-82, 1996.
93. Pu LQ, Sniderman AD, Brassard R, et al: Enhanced revascularization of the ischemic limb by angiogenic therapy. Circulation 88: 208-215, 1993.
94. Kim HJ, Jang SY, Park JI, et al: Vascular endothelial growth factor-induced angiogenic gene therapy in patients with peripheral artery disease. Exp Mol Med 36: 336-344, 2004.
95. Morishita R, Aoki M, Hashiya N, et al: Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease. Hypertension 44: 203-209, 2004.
96. Miyamoto M, Yasutake M, Takano H, et al: Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetrofosmin (TF) perfusion scintigraphy. Cell Transplant 13: 429-437, 2004.
97. Tateishi-Yuyama E, Matsubara H, Murohara T, et al ; Therapeutic Angiogenesis using Cell Transplantation (TACT) Study Investigators: Therapeutic angiogenesis for patients with limb ischemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 360: 427-435, 2002.
98. Esato K, Hamano K, Li TS, et al: Neovascularization induced by autologous bone marrow cell implantation in peripheral arterial disease. Cell Transplant 11: 747-752, 2002.
99. Iba O, Matsubara H, Nozawa Y, et al: Angiogenesis by implantation of peripheral blood mononuclear cells and platelets into ischemic limbs. Circulation 106: 2019-2025, 2002.